SITE015-0030

SITE015 (POL) › SITE015-0030

SITE015-0030

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2025-09-28

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-07 (study day 154); relationship: NOT RELATED

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-08 (study day 124); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.